Safety of DCVAC/LuCa combined with chemotherapy for treating advanced non-small cell lung cancer / 上海交通大学学报(医学版)
Journal of Shanghai Jiaotong University(Medical Science)
;
(12): 923-928, 2018.
Article
in Chinese
| WPRIM
| ID: wpr-843636
ABSTRACT
Objective:
To evaluate the safety of DCVAC/LuCa combined with pemetrexed/carboplatin in patients with stage non-small cell lung cancer (NSCLC).Methods:
A total of 20 newly diagnosed stage , non-squamous, wild-type epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) negative or unknown NSCLC patients were randomized into test group (n=10) and control group (n=10). Test group received pemetrexed/ carboplatin chemotherapy (4-6 cycles), combined with DCVAC/LuCa treatment in the third cycle, followed by pemetrexed monotherapy in combination with DCVAC/LuCa; control group received pemetrexed/carboplatin chemotherapy (4-6 cycles), followed by pemetrexed alone. The efficiency of the patients in two groups was evaluated and adverse effects (AEs) were collected and analyzed.Results:
There was a significant positive correlation between DCVAC/LuCa transfusion dose and progression-free survival (PFS) (r=0.773, P=0.009). The common AEs in both groups were chemotherapy related leukopenia, hemoglobin decrease etc. All AEs were grade 1 or 2 according to common terminology criteria for adverse events (CTCAE) V4.03, and there were no grade 4 toxicities or treatment-related deaths. One patient in test group got non-infectious fever and body ache, and returned to normal without treatment.Conclusion:
In patients with stage NSCLC, DCVAC/LuCa therapy is well tolerated with the favorable safety.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Controlled clinical trial
Language:
Chinese
Journal:
Journal of Shanghai Jiaotong University(Medical Science)
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS